Incretin-based therapies, such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonists (GIP/GLP-1 RAs) have emerged as transformative treatments for managing obesity and cardiometabolic risk. Here, GCG is linked to obesity disorder.